Joshua Barocas
Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Opioid-Related Disorders | 27 | 2023 | 502 | 9.360 |
Why?
| Drug Overdose | 19 | 2023 | 331 | 6.180 |
Why?
| Substance Abuse, Intravenous | 11 | 2022 | 107 | 5.910 |
Why?
| Hepatitis C | 10 | 2022 | 235 | 3.890 |
Why?
| Endocarditis | 6 | 2023 | 36 | 3.480 |
Why?
| Buprenorphine | 8 | 2023 | 169 | 2.760 |
Why?
| Substance-Related Disorders | 9 | 2023 | 1023 | 2.690 |
Why?
| Analgesics, Opioid | 19 | 2023 | 917 | 2.420 |
Why?
| Pharmaceutical Preparations | 6 | 2021 | 172 | 2.320 |
Why?
| Naloxone | 2 | 2021 | 113 | 2.180 |
Why?
| Epidemics | 3 | 2022 | 79 | 2.130 |
Why?
| Central Nervous System Stimulants | 2 | 2022 | 153 | 2.110 |
Why?
| Hepatitis C, Chronic | 4 | 2021 | 156 | 2.050 |
Why?
| HIV Infections | 10 | 2022 | 2744 | 1.940 |
Why?
| Endocarditis, Bacterial | 4 | 2023 | 43 | 1.870 |
Why?
| Amphetamine-Related Disorders | | | 36 | NaN |
Why?
| Hepacivirus | 8 | 2022 | 237 | 1.770 |
Why?
| Massachusetts | 7 | 2023 | 159 | 1.740 |
Why?
| Narcotic Antagonists | 4 | 2022 | 162 | 1.690 |
Why?
| Drug Users | 3 | 2022 | 44 | 1.580 |
Why?
| Prisoners | 2 | 2022 | 144 | 1.470 |
Why?
| Soft Tissue Infections | 2 | 2021 | 35 | 1.390 |
Why?
| Cost-Benefit Analysis | 10 | 2023 | 617 | 1.350 |
Why?
| Buprenorphine, Naloxone Drug Combination | 3 | 2022 | 9 | 1.320 |
Why?
| Humans | 78 | 2023 | 129706 | 1.270 |
Why?
| Harm Reduction | 2 | 2020 | 31 | 1.270 |
Why?
| Anti-Infective Agents | 2 | 2022 | 249 | 1.210 |
Why?
| Hospitalization | 7 | 2022 | 2091 | 1.160 |
Why?
| Opiate Substitution Treatment | 5 | 2022 | 140 | 1.110 |
Why?
| Pneumonia, Viral | 3 | 2020 | 361 | 1.080 |
Why?
| Coronavirus Infections | 3 | 2020 | 355 | 1.080 |
Why?
| Prevalence | 10 | 2023 | 2557 | 1.070 |
Why?
| Housing | 3 | 2023 | 132 | 1.040 |
Why?
| Fentanyl | 2 | 2023 | 83 | 1.030 |
Why?
| Homeless Youth | | | 18 | NaN |
Why?
| Mobile Health Units | | | 22 | NaN |
Why?
| Epidemiological Monitoring | | | 50 | NaN |
Why?
| Patient Isolation | 2 | 2021 | 14 | 0.920 |
Why?
| Crime | | | 58 | NaN |
Why?
| Decision Trees | | | 90 | NaN |
Why?
| Adult | 27 | 2023 | 35596 | 0.890 |
Why?
| Methamphetamine | | | 57 | NaN |
Why?
| Referral and Consultation | 3 | 2022 | 731 | 0.870 |
Why?
| United States | 16 | 2023 | 14078 | 0.860 |
Why?
| Substance Abuse Treatment Centers | 2 | 2020 | 42 | 0.860 |
Why?
| Male | 32 | 2023 | 63544 | 0.850 |
Why?
| Antiviral Agents | 5 | 2022 | 709 | 0.840 |
Why?
| Young Adult | 11 | 2022 | 12363 | 0.820 |
Why?
| Health Personnel | 2 | 2020 | 645 | 0.800 |
Why?
| Mass Screening | 6 | 2020 | 1130 | 0.780 |
Why?
| Preventive Health Services | 2 | 2020 | 145 | 0.780 |
Why?
| Hospital Administration | 1 | 2021 | 22 | 0.760 |
Why?
| Crisis Intervention | 1 | 2021 | 34 | 0.760 |
Why?
| Female | 30 | 2023 | 68562 | 0.750 |
Why?
| Criminal Law | 1 | 2021 | 30 | 0.740 |
Why?
| Hospital Units | 1 | 2021 | 21 | 0.730 |
Why?
| Convalescence | 1 | 2021 | 18 | 0.730 |
Why?
| Liver Cirrhosis | 2 | 2022 | 278 | 0.720 |
Why?
| Communicable Diseases | 2 | 2021 | 143 | 0.710 |
Why?
| Health Communication | 1 | 2021 | 42 | 0.710 |
Why?
| Public Health | 3 | 2023 | 498 | 0.710 |
Why?
| Catheterization, Peripheral | | | 104 | NaN |
Why?
| Residential Treatment | 1 | 2020 | 31 | 0.710 |
Why?
| Self Report | | | 798 | NaN |
Why?
| Pre-Exposure Prophylaxis | 1 | 2022 | 202 | 0.650 |
Why?
| Mental Disorders | 2 | 2022 | 1025 | 0.650 |
Why?
| Safety-net Providers | 1 | 2021 | 109 | 0.650 |
Why?
| Middle Aged | 15 | 2023 | 31103 | 0.630 |
Why?
| Immunization Programs | 1 | 2020 | 218 | 0.620 |
Why?
| Needle-Exchange Programs | 2 | 2015 | 7 | 0.610 |
Why?
| Socioeconomic Factors | 2 | 2020 | 1212 | 0.600 |
Why?
| Research Design | 2 | 2023 | 1048 | 0.590 |
Why?
| Delivery of Health Care | 2 | 2021 | 904 | 0.580 |
Why?
| Adolescent | 11 | 2022 | 20355 | 0.570 |
Why?
| Sustained Virologic Response | 1 | 2017 | 35 | 0.560 |
Why?
| Diagnostic Tests, Routine | 1 | 2018 | 105 | 0.560 |
Why?
| Decision Support Techniques | 1 | 2021 | 388 | 0.550 |
Why?
| Delivery of Health Care, Integrated | 1 | 2019 | 248 | 0.520 |
Why?
| Patient Discharge | 1 | 2020 | 862 | 0.510 |
Why?
| Zinc | 1 | 2019 | 291 | 0.510 |
Why?
| Outpatients | 2 | 2020 | 366 | 0.510 |
Why?
| Social Determinants of Health | 1 | 2019 | 218 | 0.500 |
Why?
| Guidelines as Topic | 1 | 2017 | 261 | 0.500 |
Why?
| Pandemics | 8 | 2022 | 1526 | 0.500 |
Why?
| Anti-HIV Agents | 1 | 2022 | 744 | 0.490 |
Why?
| Retrospective Studies | 8 | 2022 | 14669 | 0.490 |
Why?
| Monte Carlo Method | 3 | 2021 | 143 | 0.490 |
Why?
| Criminals | 1 | 2015 | 33 | 0.480 |
Why?
| Education | 1 | 2015 | 98 | 0.470 |
Why?
| Blastomyces | 1 | 2014 | 8 | 0.460 |
Why?
| Blastomycosis | 1 | 2014 | 9 | 0.460 |
Why?
| Emergency Medical Services | 1 | 2022 | 645 | 0.460 |
Why?
| Boston | 4 | 2021 | 90 | 0.440 |
Why?
| HIV Seropositivity | 1 | 2014 | 119 | 0.440 |
Why?
| Advance Directives | 1 | 2014 | 79 | 0.440 |
Why?
| Peritonitis | 1 | 2014 | 82 | 0.440 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2022 | 829 | 0.430 |
Why?
| Alcohol Drinking | 1 | 2019 | 745 | 0.410 |
Why?
| Naltrexone | 2 | 2021 | 86 | 0.410 |
Why?
| Cohort Studies | 4 | 2021 | 5410 | 0.370 |
Why?
| Quarantine | 2 | 2021 | 28 | 0.360 |
Why?
| Injections | 2 | 2021 | 174 | 0.360 |
Why?
| Colorado | | | 4471 | NaN |
Why?
| Vulnerable Populations | 2 | 2021 | 155 | 0.330 |
Why?
| Ohio | 2 | 2022 | 153 | 0.300 |
Why?
| Risk-Taking | 2 | 2021 | 361 | 0.300 |
Why?
| Cross-Sectional Studies | 4 | 2022 | 5050 | 0.290 |
Why?
| Coinfection | 2 | 2019 | 133 | 0.290 |
Why?
| Health Services Accessibility | 3 | 2022 | 908 | 0.290 |
Why?
| Kidney Transplantation | 1 | 2014 | 638 | 0.290 |
Why?
| Risk Factors | 4 | 2021 | 9832 | 0.260 |
Why?
| Wisconsin | 3 | 2014 | 102 | 0.250 |
Why?
| Bayes Theorem | 1 | 2023 | 367 | 0.240 |
Why?
| Costs and Cost Analysis | 1 | 2021 | 211 | 0.240 |
Why?
| Spatio-Temporal Analysis | | | 27 | NaN |
Why?
| Hospitals, Psychiatric | | | 23 | NaN |
Why?
| Aged | 6 | 2021 | 22113 | 0.230 |
Why?
| Patient Acceptance of Health Care | 3 | 2023 | 776 | 0.230 |
Why?
| Health Policy | 3 | 2022 | 364 | 0.220 |
Why?
| Prisons | | | 83 | NaN |
Why?
| Primary Health Care | 3 | 2023 | 1668 | 0.210 |
Why?
| Cities | 1 | 2023 | 101 | 0.210 |
Why?
| Life Expectancy | 1 | 2023 | 55 | 0.200 |
Why?
| Inpatients | 3 | 2022 | 456 | 0.200 |
Why?
| Quality-Adjusted Life Years | 2 | 2020 | 116 | 0.200 |
Why?
| Age Factors | 2 | 2020 | 3145 | 0.190 |
Why?
| International Cooperation | 1 | 2022 | 173 | 0.190 |
Why?
| Arkansas | 1 | 2021 | 15 | 0.190 |
Why?
| Immunogenicity, Vaccine | 1 | 2022 | 31 | 0.190 |
Why?
| Ambulances | 1 | 2022 | 51 | 0.190 |
Why?
| Colorectal Neoplasms | 1 | 2009 | 731 | 0.190 |
Why?
| Models, Economic | 1 | 2021 | 55 | 0.190 |
Why?
| Needle Sharing | 1 | 2021 | 10 | 0.190 |
Why?
| Delphi Technique | 1 | 2022 | 219 | 0.180 |
Why?
| Markov Chains | 1 | 2021 | 124 | 0.180 |
Why?
| Evidence-Based Practice | 2 | 2023 | 215 | 0.180 |
Why?
| Quality of Life | 3 | 2022 | 2712 | 0.180 |
Why?
| Interrupted Time Series Analysis | 1 | 2021 | 52 | 0.180 |
Why?
| Prescriptions | 1 | 2021 | 69 | 0.180 |
Why?
| Health Services | 1 | 2021 | 108 | 0.180 |
Why?
| Homosexuality, Male | 1 | 2022 | 180 | 0.180 |
Why?
| Drug Resistance, Viral | 2 | 2022 | 110 | 0.180 |
Why?
| Drug Compounding | 1 | 2021 | 97 | 0.180 |
Why?
| Betacoronavirus | 2 | 2020 | 266 | 0.180 |
Why?
| Catheterization, Central Venous | | | 99 | NaN |
Why?
| Intersectoral Collaboration | 1 | 2020 | 61 | 0.170 |
Why?
| Sex Factors | 2 | 2020 | 1952 | 0.170 |
Why?
| Prescription Drugs | 1 | 2021 | 116 | 0.170 |
Why?
| Social Isolation | 1 | 2020 | 61 | 0.170 |
Why?
| Communicable Disease Control | 1 | 2020 | 74 | 0.170 |
Why?
| Demography | 1 | 2020 | 282 | 0.170 |
Why?
| Patient Advocacy | 1 | 2020 | 73 | 0.170 |
Why?
| Public Health Administration | 1 | 2020 | 75 | 0.160 |
Why?
| Russia | 1 | 2019 | 12 | 0.160 |
Why?
| Clinical Laboratory Techniques | 1 | 2020 | 97 | 0.160 |
Why?
| Liver Cirrhosis, Alcoholic | 1 | 2019 | 17 | 0.160 |
Why?
| New York | 1 | 2020 | 127 | 0.160 |
Why?
| Heart Valve Prosthesis Implantation | 1 | 2022 | 198 | 0.160 |
Why?
| Age Distribution | 2 | 2018 | 380 | 0.160 |
Why?
| Sex Distribution | 2 | 2018 | 361 | 0.160 |
Why?
| Health Status | | | 751 | NaN |
Why?
| Randomized Controlled Trials as Topic | 1 | 2020 | 1379 | 0.150 |
Why?
| Narcotics | 1 | 2018 | 47 | 0.150 |
Why?
| Needs Assessment | 1 | 2020 | 363 | 0.150 |
Why?
| Medicaid | 1 | 2022 | 447 | 0.150 |
Why?
| Urban Population | 1 | 2021 | 442 | 0.150 |
Why?
| Surgeons | 1 | 2022 | 279 | 0.140 |
Why?
| Uridine Monophosphate | 1 | 2017 | 15 | 0.140 |
Why?
| Child | 5 | 2021 | 20963 | 0.140 |
Why?
| Fluorenes | 1 | 2017 | 39 | 0.140 |
Why?
| Proportional Hazards Models | 1 | 2020 | 1227 | 0.140 |
Why?
| Rural Population | 1 | 2021 | 507 | 0.140 |
Why?
| Sofosbuvir | 1 | 2017 | 57 | 0.140 |
Why?
| Disease Management | 1 | 2021 | 596 | 0.140 |
Why?
| Mental Health Services | 1 | 2021 | 398 | 0.140 |
Why?
| Ribavirin | 1 | 2017 | 92 | 0.130 |
Why?
| Computer Simulation | 1 | 2021 | 947 | 0.130 |
Why?
| Benzimidazoles | 1 | 2017 | 158 | 0.130 |
Why?
| Obesity | 1 | 2009 | 2851 | 0.130 |
Why?
| Physician-Patient Relations | 1 | 2020 | 537 | 0.130 |
Why?
| Telemedicine | | | 792 | NaN |
Why?
| Midwestern United States | 1 | 2015 | 41 | 0.120 |
Why?
| Recurrence | 1 | 2018 | 1016 | 0.120 |
Why?
| Multivariate Analysis | 1 | 2019 | 1507 | 0.120 |
Why?
| Skin | 1 | 2020 | 737 | 0.120 |
Why?
| Vaccination | 2 | 2020 | 1362 | 0.120 |
Why?
| Viral Load | 1 | 2017 | 449 | 0.120 |
Why?
| Incidence | 2 | 2020 | 2658 | 0.120 |
Why?
| Health Promotion | 1 | 2021 | 734 | 0.120 |
Why?
| Amphotericin B | 1 | 2014 | 29 | 0.110 |
Why?
| Surveys and Questionnaires | 4 | 2015 | 5396 | 0.110 |
Why?
| Kentucky | 1 | 2022 | 40 | 0.110 |
Why?
| Drug Therapy, Combination | 1 | 2017 | 1024 | 0.110 |
Why?
| Epidemiologic Methods | 1 | 2014 | 75 | 0.110 |
Why?
| Severity of Illness Index | 2 | 2020 | 2783 | 0.110 |
Why?
| RNA, Viral | 1 | 2017 | 622 | 0.110 |
Why?
| Antifungal Agents | 1 | 2014 | 132 | 0.110 |
Why?
| Early Diagnosis | 1 | 2014 | 235 | 0.100 |
Why?
| Professional-Patient Relations | 1 | 2014 | 144 | 0.100 |
Why?
| Social Stigma | 1 | 2014 | 112 | 0.100 |
Why?
| Genotype | 1 | 2017 | 1836 | 0.100 |
Why?
| Patient Education as Topic | 1 | 2009 | 745 | 0.100 |
Why?
| Anti-Bacterial Agents | 1 | 2022 | 1719 | 0.090 |
Why?
| Physicians, Primary Care | 1 | 2014 | 233 | 0.090 |
Why?
| Methadone | 1 | 2021 | 92 | 0.090 |
Why?
| Advance Care Planning | 1 | 2014 | 206 | 0.090 |
Why?
| Physicians | 1 | 2020 | 852 | 0.090 |
Why?
| North America | 2 | 2023 | 293 | 0.090 |
Why?
| Internal Medicine | 1 | 2013 | 249 | 0.090 |
Why?
| Fear | 1 | 2014 | 318 | 0.090 |
Why?
| Pregnancy, High-Risk | 1 | 2010 | 12 | 0.090 |
Why?
| Recreation Therapy | 1 | 2010 | 5 | 0.090 |
Why?
| Bed Rest | 1 | 2010 | 14 | 0.090 |
Why?
| Music Therapy | 1 | 2010 | 22 | 0.080 |
Why?
| Infant, Newborn | 1 | 2021 | 5752 | 0.080 |
Why?
| Decision Making | 1 | 2016 | 842 | 0.080 |
Why?
| Education, Medical, Graduate | 1 | 2013 | 438 | 0.080 |
Why?
| Chronic Disease | 1 | 2014 | 1721 | 0.080 |
Why?
| Internship and Residency | 2 | 2014 | 1056 | 0.070 |
Why?
| Attitude of Health Personnel | 1 | 2014 | 1092 | 0.070 |
Why?
| Counseling | 1 | 2009 | 384 | 0.060 |
Why?
| Anorexia | 1 | 2005 | 19 | 0.060 |
Why?
| Los Angeles | | | 61 | NaN |
Why?
| Pregnancy Complications | 1 | 2010 | 488 | 0.060 |
Why?
| Cachexia | 1 | 2005 | 60 | 0.060 |
Why?
| Recovery of Function | 1 | 2008 | 643 | 0.060 |
Why?
| Community Participation | | | 127 | NaN |
Why?
| Healthcare Disparities | 1 | 2009 | 571 | 0.050 |
Why?
| Government | 1 | 2022 | 11 | 0.050 |
Why?
| Organizations | 1 | 2022 | 23 | 0.050 |
Why?
| Treatment Outcome | 1 | 2017 | 10299 | 0.050 |
Why?
| Neoplasms | 2 | 2008 | 2435 | 0.050 |
Why?
| Public Opinion | 1 | 2022 | 65 | 0.050 |
Why?
| Syringes | 1 | 2022 | 41 | 0.050 |
Why?
| Oregon | 1 | 2021 | 68 | 0.050 |
Why?
| Stress, Psychological | 1 | 2010 | 1051 | 0.050 |
Why?
| Immunization, Secondary | 1 | 2022 | 89 | 0.050 |
Why?
| Vaccines, Synthetic | 1 | 2022 | 134 | 0.050 |
Why?
| Public Health Practice | 1 | 2022 | 64 | 0.050 |
Why?
| British Columbia | 1 | 2020 | 14 | 0.040 |
Why?
| Infectious Disease Medicine | 1 | 2020 | 12 | 0.040 |
Why?
| Invasive Fungal Infections | 1 | 2020 | 11 | 0.040 |
Why?
| Human Rights | 1 | 2020 | 17 | 0.040 |
Why?
| Federal Government | 1 | 2020 | 26 | 0.040 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 1291 | 0.040 |
Why?
| Health Care Rationing | 1 | 2020 | 60 | 0.040 |
Why?
| State Government | 1 | 2020 | 43 | 0.040 |
Why?
| Delayed-Action Preparations | 1 | 2021 | 178 | 0.040 |
Why?
| Canada | 1 | 2021 | 355 | 0.040 |
Why?
| Hepatitis B | 1 | 2020 | 61 | 0.040 |
Why?
| Comparative Effectiveness Research | 1 | 2020 | 151 | 0.040 |
Why?
| Health Education | 1 | 2022 | 339 | 0.040 |
Why?
| Infection Control | 1 | 2020 | 136 | 0.040 |
Why?
| Specialization | 1 | 2020 | 145 | 0.040 |
Why?
| Bacteremia | 1 | 2020 | 190 | 0.040 |
Why?
| Regression Analysis | 1 | 2020 | 992 | 0.040 |
Why?
| Patient Compliance | 1 | 2022 | 566 | 0.040 |
Why?
| Communication | 1 | 2022 | 844 | 0.030 |
Why?
| Societies, Medical | 1 | 2020 | 763 | 0.030 |
Why?
| Leadership | 1 | 2020 | 358 | 0.030 |
Why?
| Prospective Studies | 2 | 2023 | 7131 | 0.030 |
Why?
| Antibodies, Monoclonal | 1 | 2022 | 1360 | 0.030 |
Why?
| Databases, Factual | 1 | 2020 | 1297 | 0.030 |
Why?
| Patient Readmission | 1 | 2020 | 675 | 0.030 |
Why?
| Behavior Therapy | 1 | 2014 | 240 | 0.020 |
Why?
| Focus Groups | 1 | 2013 | 456 | 0.020 |
Why?
| Watchful Waiting | 1 | 2010 | 66 | 0.020 |
Why?
| Qualitative Research | 1 | 2013 | 1207 | 0.020 |
Why?
| Sickness Impact Profile | 1 | 2005 | 54 | 0.020 |
Why?
| Psychometrics | 1 | 2005 | 681 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2008 | 3054 | 0.010 |
Why?
| Pregnancy | 1 | 2010 | 6274 | 0.010 |
Why?
| Prognosis | 1 | 2005 | 3801 | 0.010 |
Why?
| Risk Assessment | 1 | 2005 | 3297 | 0.010 |
Why?
|
|
Barocas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|